{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-018518","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.514567+00:00","generated_at":"2026-06-13T17:03:30.795636+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Stockholders approve 6M share increase under 2020 equity plan and adoption of 2023 ESPP","bullets":["At June 21 annual meeting, stockholders approved amendment to 2020 equity incentive plan adding 6,000,000 shares.","Stockholders approved the 2023 Employee Stock Purchase Plan.","Elected directors Stephen S. Yoder, Michael Richman, and Matthew L. Sherman as Class III directors.","Ratified Ernst & Young as independent auditor for FY2023; approved say-on-pay compensation on non-binding basis."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-018518","json":"https://secwatch.observer/filing/0001437749-23-018518.json","markdown":"https://secwatch.observer/filing/0001437749-23-018518.md","text":"https://secwatch.observer/filing/0001437749-23-018518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923018518/0001437749-23-018518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923018518/pirs20230622_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:03:30.795636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20bd97bcd29abfe55cb9a5a0b446a0d22ff65968","claim":"PALVELLA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent auditor at the 2023-06-21 meeting.","evidence_excerpt":"4. Auditor Ratification Votes For Votes Against Votes Abstained Broker Non-Votes 44,353,310 96,301 394,192 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923018518/0001437749-23-018518-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"4de4b7a609cee2bd31c2fab79f8f6e5c9073e752","claim":"PALVELLA THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-21 meeting.","evidence_excerpt":"5. Say on Pay Votes For Votes Against Votes Abstained Broker Non-Votes 17,227,404 2,828,509 5,556,466 19,231,424","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923018518/0001437749-23-018518-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"586fb8eec81fa8769866c8b6714ef38a9c34048d","claim":"PALVELLA THERAPEUTICS, INC. shareholders approved Approval of amendment to the 2020 EIP at the 2023-06-21 meeting.","evidence_excerpt":"2. 2020 EIP Amendment Approval Votes For Votes Against Votes Abstained Broker Non-Votes 18,811,753 6,306,669 493,957 19,231,424","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923018518/0001437749-23-018518-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"5bf7607cbb22863e54e5682feff1ce6dfb7d3588","claim":"PALVELLA THERAPEUTICS, INC. shareholders approved Approval of 2023 ESPP at the 2023-06-21 meeting.","evidence_excerpt":"3. 2023 ESPP Approval Votes For Votes Against Votes Abstained Broker Non-Votes 19,672,797 410,705 5,528,877 19,231,424","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923018518/0001437749-23-018518-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"7c8bf8010f6a0ee9a7a3f6cd5af4ec7d4b9aa772","claim":"PALVELLA THERAPEUTICS, INC. shareholders approved Election of Directors at the 2023-06-21 meeting.","evidence_excerpt":"1. Election of Directors Name Votes For Votes Withheld Broker Non-Votes Stephen S. Yoder 25,191,766 420,613 19,231,424 Michael Richman 23,534,942 2,077,437 19,231,424 Matthew L. Sherman, M.D. 25,191,653 420,726 19,231,424","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923018518/0001437749-23-018518-index.htm","confidence":1.0,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}